Processing of ovine cardiac valve allografts: 3. Implantation following antimicrobial treatment and preservation

Cell and Tissue Banking

Volumn 3, Issue 2, 2002, Pages 105-119

  Neves, J ^a   Abecassis, M ^a   Santiago, T ^b   Ramos, T ^c   Melo, J ^a   Gruys, E ^d   Hulskamp Kock, C ^d   Ultee, A ^d   Verkaar, E L C ^d   Lenstra, J A ^d   Goffin, Y A ^e   Vanderkelen, A ^e   van Hoeck, B ^e   Hunt, C J ^f   Pegg, D E ^g  

^a SANTA CRUZ HOSPITAL   (Portugal)

^b Instituto do Coracao   (Portugal)

^c Centro de Criobiologia Cardiovasc   (Portugal)

^d UTRECHT UNIVERSITY   (Netherlands)

^e QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^f East Anglia Blood Centre   (United Kingdom)

^g UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Banking; Cardiac; Heart; Implantation; Transplantation; Valve

Indexed keywords

ACEPROMAZINE MALEATE; AMINOPHYLLINE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFOXITIN; DEXAMETHASONE; DIGOXIN; DIHYDROSTREPTOMYCIN; DIMETHYL SULFOXIDE; DNA FRAGMENT; FUROSEMIDE; GENTAMICIN; GLYCEROL; HEPARIN; MICROSATELLITE DNA; PENICILLIN G; PERACETIC ACID; PROCAINE; VANCOMYCIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; BIOMECHANICS; CELL DESTRUCTION; CELL GROWTH; CONTROLLED STUDY; CRYOPRESERVATION; DESCENDING AORTA; DNA DETERMINATION; DONOR; EXPLANT; HEART PRESERVATION; MICROMORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; SHEEP; THORACIC AORTA;

EID: 0242584852     PISSN: 13899333     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022819115765     Document Type: Article

References (38)

1. Aidulis D., Pegg D.E., Hunt C.J., Goffin Y.A., Vanderkelen A., van Hoeck B. et al. 2002. Processing of ovine cardiac valve allografts: 1. Effects of preservation method on structure and mechanical properties. Cell and Tissue Banking (submitted).
2. Amann K. and Ritz E. 1998. Cardiovascular abnormalities in ageing and in uraemia - only analogy or shared pathomechanisms? Nephrol. Dial. Transplant. 13: 6-11.
3. Angell W.W., Angell J.D., Oury J.H., Lamberti J.J. and Grehl T.M. 1987. Long-term follow-up of viable frozen aortic homografts. A viable homograft valve bank. J. Thorac. Surg. 93: 815-822.
4. Barratt-Boyes B.G. 1964. Homograft aortic valve replacement and aortic incompetence and stenosis. Thorax 19: 131-150.
5. Barratt-Boyes B.G., Roche A.H.G., Subramanyan R., Pemberton J.R. and Whitlock R.M.L. 1978. Long-term follow-up on patients with the antibiotic sterilised aortic homograft valve inserted freehand in the aortic position. Circulation 75: 768-777.
6. Beech P.M., Bowman F.O., Kaiser G.A. and Malm J.R. 1973. Frozen irradiated aortic valve homografts. NY State I Med. 19: 651-654.
7. Braun J., Hazekamp, M.G., Koolbergen D.R., Sugihara H., Goffin Y.A., Huysmans H.A. et al. 1997. Identification of host and donor cells in porcine homograft heart valve explants by fluorescence in situ hybridization. J. Pathol. 183: 99-104.
8. Cattell M.A., Hasleton P.S. and Anderson J.C. 1993. Increased elastin content and decreased elastin concentration may be predisposing factors in dissecting aneurisms of human thoracic aorta. Cardiovasc. Res. 27: 176-181.
9. Dossche K., Delariveire A., Morshuis W., Schepens M. and Ernst J. 1997. Aortic root replacement with human tissue valves in aortic valve endocarditis. Europ. J. Cardio. Thor. Surg. 12: 47-54.
10. Farrington M., Wreghitt T., Matthews I., Scarr D., Sutehall G., Hunt C.J. et al. 2002. Processing of cardiac valve allografts: 2. Effects of antimicrobial treatment on sterility, structure and mechanical properties. Cell and Tissue Banking (submitted).
11. Goffin Y.A., Henriques de Gouveia R., Szombathelyi T., Toussaint M.J. and Gruys E. 1997. Morphologic study of homograft valves before and after cryopreservation and after short-term implantation in patients. Cardiovasc. Pathol. 1: 35-42.
12. Goffin Y.A., Black M.M. and Lawford P.V. 1990. The stability and performance of bioprosthetic heart valves. In: Current Perspectives on Implantable Devices Vol. 2. JAI Press, Greenwich, Connecticut, USA, pp. 65-120.
13. Goffin Y.A., Grandmougin D. and Van Hoeck B. 1996. Banking of cryopreserved valves in Europe: Assessment of a 5-year operation in an international bank in Brussels. Eur. J. Cardiovasc. Surg. 10: 505-512.
14. Hazekamp M.G., Koolbergen D.R., Braun J., Sugihara H., Cornelisse C.J., Goffin Y.A. et al. 1995. In situ hybridization: a new technique to determine the origin of fibriblasts in cryopreserved aortic homograft valve explants. J. Thorac. Cardiovasc. Surg. 110: 248-257.
15. Hokken R.B., van Herwerden L.A., Taams M.A., Thijssen H.J.M., Mochtar B. and Bos E. 1994. Aortaklepvervanging met menselijke aortale donorkleppen. Ned. Tijdschr. Geneeskd. 138: 608-613.
16. Kerwin A.J., Lenkei S.C. and Wilson D.R. 1962. Aortic-valve homograft in the treatment of aortic insufficiency. Report of nine cases, with one followed for six years. New Engl. J. Med. 266: 852-857.
17. Kunzelman K.S., Quick D.W. and Coc F. 1998. Altered collagen concentration in mitral valve leaflets: Biochemical and finite element analysis. Ann. Thorac. Surg 66: 198-205.
18. Lis Y., Burleigh M.C., Parker D.J., Child A.H., Hogg J. and Davies M.J. 1987. Biochemical characterization of individual normal floppy and rheumatic human mitral valves. Biochem J. 15: 597-603.
19. Melo J.Q., Monteiro C., Neves J., Santos R., Martins A., Ramos S. et al. 1995. The allograft valve in aortic valve replacement and heart transplant patients - Genetic assessment of the origin of the cells using DNA profiles. J. Thorac. Cardiovasc. Surg 109: 218-223.
20. Mujumbap V.S. and Tyagi S.C. 1999. Temporal regulation of extracellular matrix components in transition from decompensatory hypertrophy to decompensatory heart failure. J. Hypertens 17: 261-270.
21. Neves J., Monteiro C., Santos R., Martins A., Ramos S., Ramos T. et al. 1995. Histological and genetic assessment of explanted allograft valves. Ann Thorac. Surg. 60: 5141-5144.
22. Neves P., Gulbenkian S., Ramos T., Martins A.P., Caldas M.C., Mascarenhas R. et al. 1997. Mechanisms underlying regeneration of cryopreserved vascular homografts. J Thorac. Cardiovasc. Surg. 113: 1014-1021.
23. Niewold T.A., Flores Landeira J.M., van den Heuvel L.P., Ultee A., Tooten PC. and Veerkamp J.H. 1991. Characterization of proteoglycans and glycosaminoglycans in bovine renal AA-type amyloidosis. Virchows Arch B Cell Pathol. Incl. Mol. Pathol. 60: 321-328.
24. Nijman I.J.,Vastenburg J.B.L., Williams J.L., Olsaker I., Thieven U. and Lenstra J.A. 1998. Thirteen bovine microsatellite markers that are polymorphic in sheep. Animal Genetics 29: 474-475.
25. O'Brien M.F., Stafford E.G., Gardner M.A.H., Pohlner P.G., McGiffin D.C. and Gall K. 1987. A comparison of aortic valve replacement with viable cryopreserved and fresh allograft valves. With a note on chromosomal studies. J Thorac Cardiovasc Surg 94: 812-823.
26. O'Brien M.F., McGiffin D.C., Stafford E.G., Gardner M.A., Pohlner P.F., McLachlan G.J. et al. 1991. Allograft aortic valve replacement: long-term comparative clinical analysis of the viable cryopreserved and antibiotic 4°C stored valves. J Card Surg. 6: 534-543.
27. Ramos T., Neves J., Gulbenkian S., Monteiro C., Santos R., Martins A. et al. 1997. The allograft valve in aortic valve replacement and in transplanted patients. In: Yankah A.C., Yacoub M.H. and Hetzer R. (eds), Cardiac Valve Allografts. Steinkopff Verlag, Darmstadt.
28. Ross D.N. 1962. Homograft replacement of the aortic valve. Lancet ii: 487.
29. Schoen F.J., Levy R.J., Nelson A.C., Bernhard W.F., Nashef A. and Hawley M. 1985. Onset and progression of experimental bioprosthetic heart valve calcification. Lab Invest. 52: 523-532.
30. Schoen F.J., Levy R.J. and Piehler H.R. 1992. Pathological considerations in replacement cardiac valves. J. Soc. Cardiovasc. Surg. 1: 29-52.
31. Thijssen H.J.M., Bos E. and Persijn G.G. 1991. Een centrale hartkleppenbank voor transplantatie van humane hartkleppen. Ned Tijdschr Geneeskd 135: 2116-2120.
32. Valente M., Bartolotti U. and Thiene G. 1985. Ultrastructural substrates of dystrophic calcification in porcine bioprosthetic valve failure. Am J. Pathol. 119: 12-21.
33. van der Kamp A.W.M., Visser W.J., van Dongen J.M., Nauta J. and Gaijaard H. 1981. Preservation of aortic heart valves with maintenance of cell viability. J. Surg. Res. 30: 47-56.
34. van Kuppevelt T.H., Domen J.G., Cremers F.P. and Kuyper C.M. 1984a. Staining of proteoglycans in mouse lung alveoli. I. Ultrastructural localization of anionic sites. Histochem. J. 16: 657-669.
35. van Kuppevelt T.H., Cremers F.R., Domen J.G. and Kuyper C.M. 1984b. Staining of proteoglycans in mouse lung alveoli. II. Characterization of the cuprolinic blue-positive, anionic sites. Histochem. J. 16: 671-686.
36. van Kuppevelt T.H., Cremers F.P., Domen J.G., van Beuningen H.M., van den Brule AJ. and Kuyper C.M. 1985. Ultrastructural localization and characterization of proteoglycans in human lung alveoli. Eur. J. Cell. Biol. 36: 74-80.
37. van Kuppevelt T.H., Rutten T.L. and Kuyper C.M. 1987. Ultrastructural localization of proteoglycans in tissue using cuprolinic blue according to the critical electrolyte concentration method: comparison with biochemical data from literature. Histochem. J. 19: 520-526.
38. Wolner E. 1992. New aspects of the degeneration of bioprosthetic heart valves after long-term implantation. J. Thoracic. Cardiovasc. Surg. 104: 14-21.